Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-24
2000-04-04
Jones, Dwayne C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 21, 530356, 4241981, A61K 3800
Patent
active
060461640
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a therapeutic agent for diseases of periodontal tissue which comprises a basic fibroblast growth factor as an active principle and a process for treating diseases of periodontal tissue with this agent. More particularly, it relates to an agent and a process used on purpose to treat the disease developed in the periodontal tissue such as periodontal ligament, alveolar bone and cementum to induce regeneration curing (new attachment curing) which is the final object of the treatment.
BACKGROUND OF ARTS
At present, it has been clarified that periodontitis, one of diseases of periodontal tissue is mainly caused by bacteria forming colonies on tooth root surface. As a treatment thereof, main effort is laid on to maintain the periodontal tissue under plaque-free condition by mechanical removing the bacterial plaque adhered to the tooth surface mainly by scaling.
A periodontal surgery applied to serious periodontitis is also performed on purpose to improve environment so as to make oral cleaning more effective, by removing causative factors such as tartar and plaque adhered to a root surface in a periodontal pocket, and pathologic tissue in the same manner as in the above-mentioned therapy. Furthermore, recently chemotherapies with antibiotics are also tried in addition to these therapies.
However, although these therapies remove the pathologic lesion and inhibit progress of the periodontitis, they do not positively repair or regenerate destroyed periodontal tissue. A profile of postoperative curing depends on self healing ability.
Curing forms are classified into regeneration curing (new attachment curing), and reattachment curing. The regeneration curing contains a curing form of cementum morphogenesis wherein collagen fibers are embedded in the postoperatively exposed root surface (new attachment curing) develops with the regeneration of alveolar bone.
On the other hand, the reattachment is a curing containing a long epithelial attachment recognized on the root surface or the accumulation of collagen fibers onto the root surface where a functional recovery can not be desired.
Heretofore, a large number of basic and clinical studies have shown that many forms of postoperative curing forms are reattachment curing. According to histopathological studies, most reattachments are caused by epithelial attachment which formed by the down growth of epithelial cells apically directed from gingival margin, and new attachment is hard to develop.
Particularly, progressed periodontitis is accompanied by complex pocket morphogenesis and various types of osteoclasia, and the bone regeneration is impossible, where the large amount of bone resorption is observed. Melcher (Melcher, A. H.: J. Periodontol., 47, pp 256-260, 1976) has also reported that the proliferation of cells derived from periodontal ligament is necessary to the recovery of the periodontal tissue with the new attachment to the exposed root surface, and that a long junctional epithelium formation, root resorption and ankylosis develop when the cells reaching the root surface are epithelial cells, cells derived from gingiva or cells derived from bone.
From these information, the following subjects have been investigated basically or clinically on purpose to achieve the regeneration curing; down growth of epithelial cells using a highly bio-compatible filter and guides the cells derived the periodontal ligament to the root surface, materials for the resorption of the alveolar bone, and
However, they have various problems such as a irritation upon the cells in (1), the stability and antigenicity of fibronectin which is a macromolecule in (2), the necessity of the reoperation for removing of the above-mentioned filter in (3), also complexity of harvest, storage, sterilizing and the ability to be resorbed of the implant material in (4), and easy occurrence of ankylosis in (5). Therefore, the development of an agent for accelerating periodontal tissue regeneration which has safety, easiness of formulation and efficien
REFERENCES:
patent: 5158934 (1992-10-01), Ammann et al.
patent: 5368859 (1994-11-01), Dunn et al.
patent: 5372503 (1994-12-01), Elia
patent: 5397235 (1995-03-01), Elia
patent: 5405390 (1995-04-01), O'Leary et al.
Terranova et al., J. Periodontol, vol. 60, No. 6, 1989, pp. 293-301.
Nakashima, Archs Oral Biol. vol. 37, No. 3, pp. 231-236, 1992.
Cam et al., Int. J. Dev. Bio., vol. 36, No. 3, pp. 381-389, 1992.
Database WPI, Section Ch, Week 9513, Derwent Publications Ltd., London, GB; Class 804, AN 95-093773, XP002046904 & JP 07 017 876 A (Kaken Pharm. Co. Ltd.), Jan. 20, 1995, Abstract.
Amakawa Masahiro
Asano Taiji
Nakano Yoshiko
Saga Katumasa
Sugimoto Hajime
Delacroix-Muirheid C.
Jones Dwayne C.
Kaken Pharmaceutical Co. Ltd.
LandOfFree
Therapeutic agent for diseases of periodontal tissue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for diseases of periodontal tissue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for diseases of periodontal tissue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365021